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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by selective motoneurons
degeneration. There is today no clear-cut pathogenesis sequence nor any treatment. However growing evidences are in
favor of the involvement, besides neurons, of several partners such as glia and muscles. To better characterize the time
course of pathological events in an animal model that recapitulates human ALS symptoms, we investigated functional and
cellular characteristics of hSOD1
G93A mice.
Methods and Findings: We have evaluated locomotor function of hSOD1
G93A mice through dynamic walking patterns and
spontaneous motor activity analysis. We detected early functional deficits that redefine symptoms onset at 60 days of age,
i.e. 20 days earlier than previously described. Moreover, sequential combination of these approaches allows monitoring of
motor activity up to disease end stage. To tentatively correlate early functional deficit with cellular alterations we have used
flow cytometry and immunohistochemistry approaches to characterize neuromuscular junctions, astrocytes and microglia.
We show that (1) decrease in neuromuscular junction’s number correlates with motor impairment, (2) astrocytes number is
not altered at pre- and early-symptomatic ages but intraspinal repartition is modified at symptoms onset, and (3) microglia
modifications precede disease onset. At pre-symptomatic age, we show a decrease in microglia number whereas at onset of
the disease two distinct microglia sub-populations emerge.
Conclusions: In conclusion, precise motor analysis updates the onset of the disease in hSOD1
G93A mice and allows
locomotor monitoring until the end stage of the disease. Early functional deficits coincide with alterations of neuromuscular
junctions. Importantly, we identify different sets of changes in microglia before disease onset as well as at early-
symptomatic stage. This finding not only brings a new sequence of cellular events in the natural history of the disease, but it
may also provide clues in the search for biomarkers of the disease, and potential therapeutic targets.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a chronic neurodegener-
ative disease characterized by a selective degeneration of
motoneurons in the motor cortex, brainstem, and spinal cord.
Symptoms start with progressive weakness, atrophy of skeletal
muscles and paralysis that eventually lead to death. The
prevalence of ALS is of 2–5 per 100 000 individuals and the
median survival of 36 months after symptom onset. Approximately
90% of ALS patients are sporadic cases with no known genetic
component whereas 10% are familial cases. In familial ALS 20%
of the patients harbour a mutation in the gene coding for the
enzyme Cu/Zn superoxide dismutase 1 (SOD1) (for reviews see
[1,2]).
Transgenic mice over-expressing the human mutated gene for
Cu/Zn SOD1 had been created based on the identification of
missense mutations in the human SOD1 gene responsible for one
form of familial ALS [3]. The most extensively used SOD1
G93A
transgenic line harbours a mutant form of human SOD1
containing a Gly
93RAla amino acid substitution [4]. These mice
develop a dominantly inherited adult-onset paralytic disorder that
recapitulates human ALS symptoms. Disease onset is described at
around 80–90 days of age with progressive clinical weakness
followed by paralysis and death by 135 days.
Pathogenesis of motoneuron degeneration in ALS and mech-
anisms of selective vulnerability are still largely unknown although
it has been demonstrated that ALS is a complex multifactorial
disease (protein misfolding, glutamate-mediated excitotoxicity,
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cellular partners such as neuron, glial and muscle cells (for reviews
see [1,2,5,6]). Thus, there is growing interest about whether the
death phenomenon in motoneurons is indeed cell autonomous or
mediated by non-neuronal cells [7,8,9,10,11]. A better under-
standing of the role of these neighboring cells has resulted in the
recognition of the important role played by astrocytes and
microglia in health and disease (for review see [5]). Moreover,
the presence of reactive astrocytes and microglia is a hallmark of
ALS [12,13].
Studies on human cells and tissues - both normal and diseased -
are obviously critical for moving forward with any particular
therapeutic strategy, but these types of studies are limited due to
their complexity and to the limited access to biopsy material. For
this reason, it appears mandatory to better characterize the time
course of pathological events in animal models of the disease.
In this study, through dynamic walking patterns analysis of
hSOD1
G93A transgenic mice we have revised motor symptoms
onset at 60 days of age, i.e. 20 days earlier than previously
described. Moreover, sequential combination with spontaneous
motor activity analysis has allowed locomotor activity monitoring
up to the end stage of the disease.
In parallel, tissular and cellular studies have demonstrated that
early functional deficits coincide with alterations of neuromuscular
junctions. Finally, we have identified a very early cellular hallmark
of the disease in microglia, which have never been before
considered as key elements in the early pathogenesis of this disease.
Results
Locomotor function is altered at 60 days of age in
hSOD1
G93A mice
To better characterize disease onset and progression in the
hSOD1
G93A mice we have associated two behavioral tests that
allow the evaluation of locomotor function.
We have used the CatWalk
TM system to carry out an automated
dynamic gait analysis and the open field approach to record
spontaneous motor activity. Mice were tested on a weekly basis
from 50 days of age. Open field analysis was done until the end
stage of the disease whereas CatWalk
TM testing had been carried
out up to 105 days of age since then mice were too paralyzed to
achieve the test. The CatWalk
TM system yields quantitative gait
parameters, including the ‘‘relative position’’ of the paws that
correspond to the distance between front and hind footprints over
a step cycle (Figure 1 A1&A2). In a step cycle, control animals
place their hind paws in the footprint of the front paws (Figure 1B,
glossy and matt prints correspond respectively to front and hind
paws). This gait pattern is a very robust parameter in control
littermates. At 53 days of age hSOD1
G93A animals presented the
same pattern as controls (Figure 2A), whereas from 60 days
onwards, they showed a subtle but constant alteration in gait
pattern appearing as the inability to draw their hind limbs up to
the previous position of their front limbs (Figure 1C and
Figure 2B). This alteration in gait pattern increased further up
to 102 days of age (Figure 1D and Figure 2C–E). Using the
CatWalk
TM system, we thus demonstrate that locomotor alter-
ation in the hSOD1
G93A mouse model starts 20 days earlier than
described in the literature. This previous disease onset corresponds
in our experiments to the significant decrease in weight of the
mutated animals as compared to controls observed from 84 days of
age (Figure S1).
We used the open field system to measure the spontaneous
motor activity of hSOD1
G93A and control mice. We highlighted a
decreased in the mean distance covered by transgenic animals as
compared to their control littermate from 102 days of age until the
end stage of the disease (Figure 2F).
Taken together, these results demonstrate that the combined
use of CatWalk
TM and open field analysis systems allows a
thorough description of motor alterations in the hSOD1
G93A
mouse model. CatWalk
TM analysis allowed early detection of
motor symptoms and open field permitted a follow up of motor
activity up to the end stage of the disease.
Decrease in number of neuromuscular junctions
correlates with motor impairment
Such alterations of the locomotor pattern suggest an early
impairment of skeletal hind limbs muscles. This prompted us to
examine neuromuscular junctions in the gastrocnemius-soleus-plantaris
complex at symptoms onset (P60) (Figure 3C–E). Using an
enzymatic method that reveals cholinesterases we confirmed a
reduction in neuromuscular junction’s number in hSOD1
G93A
animals as compared to control littermates (99.3861.399 vs.
84.7163.931, p=0.0079). At the two pre-symptomatic ages we
examined, (P10 and P30, Figure 3A, B&E) neuromuscular
junction’s number was not different in control and transgenic
Figure 1. CatWalk
TM patterns of hSOD1
G93A mice. A1 – The
‘‘relative position’’ corresponds to the distance between the placement
of front limb and hind limb paws over one walking step. (A1 a–c) - Front
paws are represented by glossy colour and (A1 b–d) hind paws are
represented in matt. A1 - Example of a full step cycle in hSOD
G93A mice
at 90 days of age and A2 - control littermates. B - Walking pattern of
control mice, C - transgenic animals at 60 days of age and D - 90 days of
age. a: right front limb paw, b: right hind limb paw, c: left front limb
paw, d: left hind limb paw.
doi:10.1371/journal.pone.0036000.g001
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in the early onset of symptoms affecting hind limbs in hSOD1
G93A
mice.
Astrocytes number is not altered at pre-and early-
symptomatic ages but spinal repartition is modified at
symptoms onset
There is growing evidences of the involvement of glial cells in
ALS. We thus investigated possible astrocyte modifications at pre-
symptomatic and early symptomatic ages. To evaluate the total
number of astrocytes in the spinal cord of hSOD1
G93A and control
animals, we used flow cytometry analysis based on the pan-
astrocytic marker Aldh1L1 to obtain the widest astrocytic
population. We did not observe any difference in the number of
Aldh1L1
+ -astrocytes in hSOD1
G93A as compared to the controls
at both pre-symptomatic (P30; 16.5264.899 n=3 in the control
group vs. 19.7062.364 n=3 in transgenic animals) and
symptomatic ages (P60; 22.9164.954 n=4 in the controls vs.
23.8364.717 n=4 in transgenic animals) (Figure 4 and Figure
S2).
Astrogliosis is a hallmark of ALS end-stage. In order to better
quantify possible gliosis, we have used the classical astrocytic
marker GFAP. We first validated the accuracy of our FACS
approach by comparing transgenic and control animals at end-
stage of the disease (P120). As expected, spinal cords of transgenic
animals exhibit a 1.6-fold increase in the number of GFAP
+-
astrocytes (Figure S3I–L). We thus performed FACS analyses for
GFAP at pre-symptomatic (P30) and early-symptomatic (P60)
stages. This analysis did not show any significant difference
between transgenic and control animals (Figure S3A–H).
However at early symptomatic stage, we highlighted using
immunohistochemistry, differences in astrocytes repartition. Lum-
bar spinal cords from transgenic animals indeed displayed
astrogliosis in the spinal ventral gray matter as compared to the
controls (Figure 5A–B). Quantification of the mean labeling
intensity confirmed this observation since transgenic animals
presented a 1.3-fold increase of GFAP in the ventral gray matter as
compared to controls (2674652.44 n=3 vs. 20886129.1 n=3)
(Figure 5C).
These results demonstrate, using two specific markers, that there
is no difference in astrocyte number in the entire spinal cord
between control and hSOD1
G93A mice before disease onset and at
early-stage of the disease. Nevertheless, astrogliosis is already
visible in the lumbar spinal ventral horn of transgenic animals at
early-symptomatic stage.
Microglia modifications precede disease onset
A second glial cell type that may be involved in ALS is
microglia. We have used the same FACS approach to quantify the
number of microglia in the spinal cord of hSOD1
G93A and control
animals at pre- and early-symptomatic stages using the microglial
marker Iba1. Surprisingly, we have found a decrease in microglia
percentage (vs total number of cells) in the entire spinal cord at the
pre-symptomatic age (P30) in transgenic animals compared to
their control littermate (19.3760.362 n=3 for the control vs.
15.6660.094 n=3 for the transgenic; p=0.0006) (Figure 6A–D).
In order to determine microglia repartition and morphology, we
performed immunolabeling for Iba1 on lumbar spinal cord
sections from control and transgenic animals. We did not notice
any difference in microglial morphology. (Figure 6E–F).
Figure 2. Locomotor function analysis of hSOD1
G93A mice. (A–E) - CatWalk
TM gait analysis. Graphs represent the distance between the front
and hind paws on a step sequence (‘‘relative position’’; see Figure 1 for details) of control and hSOD1
G93A animals. A, B, C, D and E - Respectively 53,
60, 74, 81 and, 102 days of age. F - Open field test. Spontaneous locomotor activity represented by the mean distance covered by control and
hSOD1
G93A mice in a 8 minutes recording test over disease progression. For CatWalk
TM analysis a minimum of 7 animals and up to 13 per group and
time point were included (see selection criteria in Supplementary Figure 1). For Open field test a minimum of 20 animals were used from day 53 to
116, then due to the death of hSOD1
G93A mice, a minimum of 5 animals were analyzed (P123 to P137). Statistics: t-test; * p,0.05, ** p,0.01 and
*** p,0.001.
doi:10.1371/journal.pone.0036000.g002
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the total number of Iba1
+-microglia in the entire spinal cord
(32.5362.276 n=5 in controls vs. 28.2262.167 n=3 in
hSOD1
G93A) (Figure 7D). However, FACS analysis on transgenic
animals separated two distinct microglia sub-populations
(Figure 7A–C): one with a low level of Iba1 expression (Iba1
low
corresponding to ‘‘P3’’ area) and one with a high level of Iba1
expression (Iba1
high corresponding to ‘‘P5’’ area). Although the
total number of microglia was similar in both control and
transgenic animals, we found that percentages of the two microglia
sub-populations were different. Indeed, Iba1
low microglia is
significantly decreased in transgenic animals whereas the Iba1
high
population is increased about 2-fold in transgenic as compared to
their control littermate (respectively: Iba1
low: 30.0561.780 n=5
in controls vs. 23.5661.487 n=3 in transgenics; p=0.0474.
Iba1
high: 2.48060.523 n=5 in controls vs. 4.65760.688 n=3 in
transgenics; p=0.0445) (Figure 7D–F). This difference could
reflect a variation in activation states. In order to further
substantiate this point, we have examined Iba1 expression on
lumbar spinal cord sections from control and hSOD1
G93A
animals. We observed a clear microglial activation in the ventral
spinal horn of transgenic animals as compared to control. Indeed,
microglia from control animals displayed a small soma associated
with fine ramified processes that are characteristics of resting
microglia (Figures 7G and J) whereas transgenic animals
harbored microglia with large soma and reduced processes
complexity (Figures 7H and K). Moreover, the ventral lumbar
spinal horn of transgenic animals presented microglial density
characteristic of inflammatory state (Figures 7I and L).
Interestingly, activated microglia were mainly located in close
vicinity of morphologically altered motoneurons (reduced size and
condensated nuclei) (arrowheads in Figure 7K–L).
Thus, different sets of changes in microglia before disease onset,
on the one hand, as well as at early-symptomatic stage, on the
other hand, are in favor of their potential involvement in the early
phases of the disease.
Discussion
Generalities
Our findings on the locomotor function of hSOD1
G93A mice
indicate that deficits are detectable from 60 days of age, this
Figure 3. Neuromuscular junctions in the gastrocnemius-soleus-plantaris complex in control and hSOD1
G93A mice at pre-and early-
symptomatic ages. Neuromuscular junctions were revealed by the Karnovsky and Roots enzymatic method. A - Low magnification photograph of
the gastrocnemius-soleus-plantaris complex from a P30 control mouse. B - Low magnification photograph of the gastrocnemius-soleus-plantaris
complex from a P30 hSOD1
G93A mouse. C - High magnification photograph of the gastrocnemius from a P60 control mouse. D - High magnification
photograph of the gastrocnemius from a P60 transgenic mouse. E- Quantification of the neuromuscular junctions at two pre-symptomatic ages (P10
and P30) and at early-symptomatic age (P60). Statistics: t-test; ** p,0.01.
doi:10.1371/journal.pone.0036000.g003
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G93A mice spinal cords. The number of spinal astrocytes from hSOD1
G93A
animals and their control littermates was assessed by flow cytometry using the pan-astrocyte marker Aldh1L1. (A–C) - Representative flow cytometry
analysis dot plot astrocyte profiles. A - Negative control (without Aldh1L1 labeling). B - Control and C - hSOD1
G93A spinal astrocytes at P60. In both B -
controls and C hSOD1
G93A surrounded areas, designed as ‘‘P3’’, correspond to the labeled cells. D - Quantification of Aldh1L1
+-astrocytes in control
and hSOD1
G93A animals at pre-symptomatic (P30) and early-symptomatic (P60) stages. The X-axis represents the intensity of fluorescence and the Y-
axis the size of the cells.
doi:10.1371/journal.pone.0036000.g004
Figure 5. Spinal cord astrocytes in control and hSOD1
G93A mice at early-symptomatic stage. (A–B) - Photographs of GFAP
immunohistochemical labeling from A - control or B - hSOD1
G93A lumbar spinal cord section at early-symptomatic (P60) stage. Dotted circle in (B)
delineate astrogliosis. (C) Quantification of the mean labeling intensity per area in the lumbar spinal cord of control or hSOD1
G93A animals. Statistics:
t-test; * p,0.05. Scale bars (A–B): 50 mm.
doi:10.1371/journal.pone.0036000.g005
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with the previously admitted 80–90 days of age. Moreover we
show that a sequential combination of two behavioural tests allows
the accurate monitoring of motor alteration from disease onset
until its end stage. When looking at the periphery, we found that
early functional motor deficits correlate with a decrease in motor
end-plates number. Finally, in the spinal cord of transgenic
animals, we discovered a pre-symptomatic decrease in microglia
number, whereas astrocytes are not affected. At early symptomatic
age we describe a complex alteration of astrocyte and microglia
organization in hSOD1
G93A mice.
Locomotor function is altered at 60 days of age in
hSOD1
G93A mice
Transgenic mice on a B6SJL background carrying a high copy
number of the G93A human SOD1 mutation (B6SJL-Tg (SOD1-
G93A) 1Gur/J) is the most commonly used mouse model of ALS.
The majority of pre-clinical studies and clinical trials are based on
results obtained with this transgenic strain. So far, translation of
the results obtained in mice to human has been disappointing.
This may be due to an inaccurate characterization of the animal
model, and in particular of the lack of sensitivity of the behavioural
analysis that had been used and may not allow the complete and
precise symptoms follow up in transgenic mice.
Using an automated gait analysis system, we report early
functional deficits that redefine symptoms onset at 60 days of age,
i.e. 20 days earlier than previously described. Our results confirm
and extend recent data obtained with the digigait treadmill video
based system on the same transgenic strain [14]. However,
noteworthy is that the CatWalk
TM, through the dynamic analysis
of walking patterns, and conversely to the treadmill, does not
induce any physical exercise that could affect the lifespan of the
mice [15,16,17]. Moreover, the reproducibility of the digigait
analysis system is still under debate [18,19]. The CatWalk
TM
system seems thus better adapted for the evaluation of therapeutic
approaches. In a recent study, early motor symptoms had been
detected at 45 days of age using a rotarod in SOD1
G93A mice on a
C57/BL/6 background. In the same study modifications of step
patterns were identified around P75 using CatWalk
TM system.
One of the drawbacks of the use of the rotarod in the assessment of
a therapeutic approach is its influence on the pathophysiology of
the disease, such as increases of the lifespan and cell proliferation
that have been reported in a mouse model of motoneuron
degeneration [15]. Discrepancy in CatWalk
TM results obtained in
this study and our data could be due to the difference in genetic
background. Moreover, and conversely to the previous study, we
detect significant and reproducible motor deficits in paw
placement from day 60 to 102. We can thus conclude that using
the CatWalk
TM analysis resets early locomotor functional deficits
at 60 days of age in hSOD1
G93A mice and reinforces the accuracy
of the automated gait analysis method in neurodegenerative
diseases [20]. In the gastrocnemius muscular complex, we show
that the decrease in the number of neuromuscular junctions at 60
days of age correlates with the early symptom onset. Interestingly,
we correlate this functional deficit with the concomitant decrease
Figure 6. Spinal cord microglia in control and hSOD1
G93A mice at a pre-symptomatic stage. The number of microglia from hSOD1
G93A
animals and their control littermates was assessed by flow cytometry using the microglial marker Iba1. (A–C) - Representative flow cytometry analysis
dot plot microglia profiles. A - Negative control (without Iba1 staining). B - Control and C - hSOD1
G93A spinal microglia at P30. In both B - controls and
C - hSOD1
G93A surrounded areas, designed as ‘‘P3’’, correspond to the labeled cells. D - Quantification of Iba1
+-microglia in control and hSOD1
G93A
animals at pre-symptomatic (P30) age. (E–F) - Photographs of Iba1 immunohistochemical labeling from E - a control or F - hSOD1
G93A lumbar spinal
cord section. The X-axis represents the intensity of fluorescence and the Y-axis the size of the cells. Statistics: t-test; *** p,0.001. Scale bars 50 mm.
doi:10.1371/journal.pone.0036000.g006
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G93A mice at an early-symptomatic stage. The number of microglia from hSOD1
G93A
animals and their control littermates was assessed by flow cytometry using the microglial marker Iba1. The abscissa represents the staining intensity.
(A–C) - Representative flow cytometry analysis dot plot microglia profiles. A - Negative control (without Iba1 staining). B - Control and C - hSOD1
G93A
spinal microglia at P60. In both B - Controls and C - hSOD1
G93A surrounded areas, designed as ‘‘P3’’, correspond to the Iba1
low cells (same microglia
population as in P30 experiment). Areas designed as ‘‘P5’’ correspond to the Iba1
high cells. (D–F) - Quantifications of microglia in spinal cord of Control
and hSOD1
G93A animals at early-symptomatic (P60) age. D - Total Iba1
+-microglia, E - Iba1
low microglia and F - Iba1
high microglia. (G–I) - Photographs
of Iba1 immunohistochemical labeling from G - control or H - hSOD1
G93A lumbar spinal cord section. I - Combination of Iba1 immunolabeling and
hematoxylin on a hSOD1
G93A lumbar spinal cord section. (J–L) - High magnifications of the boxes in (G, H and I). Asterisks correspond to healthy
motoneurons. Arrowheads show degenerating motoneurons surrounding by activated microglia. The X-axis represents the intensity of fluorescence
and the Y-axis the size of the cells. Statistics: t-test; * p,0.05. Scale bars (G–I): 40 mm; (J–L): 20 mm.
doi:10.1371/journal.pone.0036000.g007
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complex. These data confirm previous results obtained [21,22]
with other enzymatic based method [23].
Moreover, we provide a complete set of evaluation of the
spontaneous locomotor activity from day 60 to the end stage of the
disease, through the association of the CatWalk
TM with the open
field. This is of importance in the perspective of translational
studies. Indeed, key issues to assess the potential effects of a given
therapeutic approach are a precise characterization of the
symptomatic period, and the accurate monitoring of the
progression of the paralysis in this mouse model. This approach
can be extended to other neuromuscular disorders.
Glial alterations at pre-and early-symptomatic ages
Astrocytes: Astrogliosis is a hallmark of amyotrophic lateral
sclerosis in patients where reactive astrocytes surround both upper
and lower motor neurons [13]. In the spinal cord of ALS patients,
GFAP-immunoreactivity is particularly noticeable in the grey
matter of the ventral horn where normally astrocytes express
GFAP at very low levels [24].
A similar pattern of astrogliosis has been described in many
transgenic ALS mouse models, although the time course of
astrogliosis, relative to motor neuron degeneration and symptoms
onset, seems to vary depending on the model. However, astrocyte
reactivity generally precedes motoneuron degeneration and
symptoms onset. In hSOD1
G37R mice, astrogliosis is indeed
described as early as 5 weeks of age whereas motoneurons death
typically occurs around 15 weeks [25]. In the hSOD1
G85R mouse
model, Bruijn et al. have shown SOD1 and ubiquitin astrocytic
inclusions as initial indicators of the disease and presence of
reactive astrocyte becomes evident at 6.5 months of age i.e. 1
month before motoneuron loss [26].
Using a combination of FACS analysis and immunohistochem-
istry, we have investigated spinal astrocyte population in
hSOD1
G93A mice at the pre- and early-symptomatic stages
(respectively P30 and P60) as determined previously. FACS
analysis did not reveal any difference in astrocyte number either
with the pan-astrocytic marker Aldh1L1 or with GFAP. However,
at the early-symptomatic stage, histological examination detected
an increase in GFAP labelling in the ventral horn of lumbar spinal
cord of transgenic animals as compared to controls. This is thus
the first description of astrogliosis occurring before motor neuron
loss in the hSOD1
G93A. Indeed, astrocyte reactivity had been
previously described at 90–100 days of age [27,28] whereas
motoneuron degeneration has been observed as early as 74 days of
age [29].
Microglia: There are growing evidences for the involvement
of microglia, the resident macrophage of the CNS, and an
immune response in ALS (for reviews see [30,31,32]). Indeed
activated microglia and T cells are one of the components of ALS
(for review see [32]). Microglia, that survey the neural environ-
ment for potential intrusion, are in constant molecular interaction
with other cell types and are characterized by an early activation
in response to injury. In a physiological context, microglia
synthesize and release trophic factors whereas in a pathological
circumstances, they rapidly switch from a resting to an activated
state. Activation results in morphological changes from ameboid to
phagocytic cells with numerous processes and proliferation.
Moreover, in a pathological context, microglia most likely play a
dual detrimental and beneficial effect. On the one hand, through
the release of neurotrophic factors and anti-inflammatory
cytokines they are hypothesized to exert a neuroprotective action
and on the other hand, the release of pro-inflammatory cytokines
and free radicals may be cytotoxic for neurons (for review see
[31]).
In ALS animal models microglia activation has been reported at
the early stage of the disease and increased with disease
progression (for review see [31]). In particular, in hSOD1
G93A
mice microglia activation in the ventral spinal horn is evident
before the previously accepted date of clinical onset (i.e. 80 days of
age) [12,27]. It has been hypothetized that in this animal model,
the dialogue between motoneurons and microglia initially protects
motoneurons (for review see [30]).
Microglial activation, revealed by CD11b labelling, had been
reported at 32 days of age in the lumbar ventral horn of
hSOD1
G93A mice [33]. In our study, we describe for the first time
a deficit in microglia number in the entire spinal cord of
hSOD1
G93A mice at very early age, i.e. 30 days of age. This
result is not in opposition with the previous study of Saxena et al.
[33] since at variance with them, we have not restricted our
analysis to the lumbar part of the spinal cord and we did not use
the same microglia markers. The deficit in microglia number that
we observed may reflect an intrinsic alteration in this specific cell
population and argues for of an immune deficit. A reduction in
number, proliferation and maturation of T cells has been recently
reported in hSOD1
G93A mice and ALS patients [34,35]; and T
cells, acting by modulation of microglia inflammatory response
have been suggested to play a neuroprotective role (for review see
[36]).
At 60 days of age, that correspond to early symptomatic stage,
we do not find a difference in total microglia number but we
identify an increase in a subpopulation of microglia that express
high levels of Iba1. This increase in Iba1 expression is a sign of an
activation of microglia [37,38], we indeed found with immuno-
histochemistry a morphology representative of activated microglia
and substantiate a previous study in hSOD1
G93A rats [39]. This
most likely reflects an early phase of proliferation since in ALS
animal models, activated microglia arise mainly from endogenous
origin rather than resulting from peripheral recruitment [40,41],
thus increase in number most likely reflects local microglia
proliferation [32].
Our examination of glial cells, that evidences a complex
sequence of alterations in astrocytes and microglia populations
before or concomitantly to motoneuron degeneration, strongly
suggests an early implication of glia in the initiation of the disease.
It may also provide clues in the search for biomarkers of the
disease, and for potential therapeutic targets.
In summary, the present study has brought forward a hitherto
unrecognized set of functional and anatomical hallmarks of the
hSOD1
G93A mouse model of ALS, thus providing new clues for
translational studies of this devastating disease.
Methods
Animals
Experimental procedures followed the European legislative,
administrative and statutory measures for animal experimentation
(86/609/EEC) and the Declaration of Helsinki. The study was
approved by the ‘‘Direction des Services Ve ´te ´rinaires de
l’He ´rault’’, France (authorization number 34118) and ratified by
the ‘‘Pre ´fecture de l’He ´rault’’, France. Every effort was made to
minimize the number of animals and their suffering. Transgenic
mice carrying the G93A human SOD1 mutation B6SJL-Tg
(SOD1-G93A) 1Gur/J (ALS mice) were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA) and bred on a B6SJL
background. Transgenic mice were identified by PCR and housed
in controlled conditions (hygrometry, temperature and 12 h light/
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groups were done as much as possible. Record of the weight was
done once a week from 56 days onward.
Behavioural analysis
CatWalk
TM: The CatWalk
TM is a video-based automated gait
analysis system that allows to determine dynamic and voluntarily
walking patterns in rodent models (Noldus, Wageningen, The
Netherlands). The principle is based on an optical technique. In a
dark room, a glass walkway floor is enlightened by a fluorescent
tube. When the animal crosses the walkway, the light is refracted
by any contact on the glass. Different paw contacts and placements
are visualized and recorded by a camera. The CatWalk
TM system
measures various aspects of locomotor pattern. Indeed, based on
the position, pressure, and surface area of each footfall, multiple
parameters are calculated, amongst those, the ‘‘relative position’’
corresponds to the distance between the placement of front and
hind paws over one walking step (Figure 1A1).
For data collection, six runs per animal were performed on a
weekly basis from day 53 and until animals were not able to do the
test. For each mouse a minimum of three runs crossed at the same
speed with 3-full step sequence patterns per run were recorded.
To avoid bias due to stress, we placed transgenic and control
littermate mice on the glass plate 7 and 3 days prior to the first
recording session. Recording sessions were stopped when the
transgenic mice were not able to correctly cross the walkway due
to hind limb paralysis.
Open field activity: Spontaneous locomotor activity of
control and transgenic mice was monitored in an open field test.
Animals were placed in an empty test arena (45645 cm box) and
movements automatically recorded by infra-red capture. We
analyzed the total distance (cm) using the Actitrack soft system
(Bioseb, Open field, Actitrack software, Vitrolles, France). Analysis
started at P53 and until the end of life of the transgenic mice;
analysis correspond to a weekly 8 minutes session preceded by
2 minutes without recording to avoid any bias due to stress.
Immunohistochemistry
Mice were anesthetized with pentobarbital (i.p), and perfused
intracardially with cold PBS followed by cold 4% paraformalde-
hyde (Sigma Aldrich, Saint Louis, USA). Spinal cords and
gastrocnemius - soleus - plantaris muscular complexes were removed
and post fixed for 24 h in 4% paraformaldehyde. Samples were
cryoprotected in sucrose 30%, included in Tissue Teck (Sakura,
Alphen aan den Rijn, Pays Bas), frozen and kept at 280uC until
processing.
Free floating spinal cord transversal sections (20 mm) were
washed twice in PBS (5 min), treated for 30 min in PBS containing
lysine (20 mM, pH 7.4) and for 15 min in 1% H2O2). Sections
were then permeabilized and blocked for 1 hour with PBS
containing bovine serum albumin (BSA, 10%) (all from Sigma
Aldrich, Saint Louis, USA) and Triton X-100 (0.1%) (Fisher
Scientific, Illkirch, France) and then incubated 48 hours at 4uC
with either Iba1 (1/1000; Wako Pure Chemical Industries, Osaka,
Japan) or GFAP (1/2000; Dako, Glostrup, Denmark) primary
antibodies diluted in the same solution.
Secondary rabbit peroxydase-conjugated antibody was used
(1:500; Jackson Immunoresearch, Carlsbad, USA). Sections were
then washed in TRIS buffer and enzymatic and revelation was
done with diaminobenzidine and H2O2 0.1% as a substrate.
Some sections were counterstained with Mayer hematoxylin
solution 0.1% for 15 minutes (Sigma Aldrich, Saint Louis, USA).
Quantifications of the mean labelling intensity were separately
and blindly done by two experimenters using the AdobeH
PhotoshopH software (Adobe, San Jose, USA). One section out
of twenty was used for quantification all along the lumbar spinal
cord.
Neuromuscular junctions labelling
For neuromuscular junctions (NMJ) labelling we followed the
protocol of Karnovsky and Roots [23]. We analyzed the entire
gastrocnemius - soleus - plantaris muscular complex on transverse
sections (16 mm). NMJ Quantification was done blindly every 3
sections.
FACS
hSOD1
G93A mice and control littermates were anesthetized
with pentobarbital (2.5 ml/kg) and intracardially perfused with
cold PBS to chase the blood. Spinal cords were dissected and then
dissociated in 750 ml PBS (Invitrogen, Carlsbad, USA), 100 ml
trypsin 13 mg/ml, 100 ml hyaluronidase 7 mg/ml, 50 ml kinurenic
acid 4 mg/ml (all from Sigma Aldrich, Saint Louis, USA), and
20 ml DNAseI 10 mg/ml (Roche, Rotkreuz, Switzerland) for
30 minutes at 37uC. Final dissociation was made by pipetting. Cell
suspension was sieved on a 40 mm sieve (BD Biosciences, Franklin
Lakes, USA). To eliminate myelin, cells were re-suspended in
PBS-0.9 M sucrose and centrifuged for 20 minutes at 750 g. The
pellet was then fixed in cold 4% paraformaldehyde for 20 minutes.
For labeling, cells were incubated 10 minutes on ice in PBS-
0.5% BSA-0.1% saponin (Sigma Aldrich, Saint Louis, USA).
Primary antibodies were diluted in the same solution at the
following dilutions: Iba1 1/500 (Wako Pure Chemical Industries,
Osaka, Japan), GFAP 1/1000 (Dako, Glostrup, Denmark),
Aldh1L1 1/1000 (Abcam, Cambridge, UK). After a 20 minutes
incubation, cells were washed with cold PBS and re-suspended
into the secondary antibody solution (donkey anti rabbit Alexa 488
1/1000 in PBS-0.5% BSA, (Invitrogen, Carlsbad, USA)) for
15 minutes on ice. Aldh1L1 labeling requires a demasking step in
sodium citrate 10 mM pH6 for 2 hrs between fixation and
blocking steps.
Cells were analyzed with a FACS ARIA (BD Biosciences,
Franklin Lakes, USA), equipped with a 488 nm Laser Sapphire
488-20. Size threshold was used to eliminate cellular debris.
Analysis and quantification have been done using the FACSDiva
software (BD Biosciences, Franklin Lakes, USA).
Statistical analysis
Data were expressed as means 6 standard error of the mean
(SEM) and comparisons between transgenic and control were
done using t-test. We used GraphPad Prism version 5.03
(GraphPad software, CA, USA).
Supporting Information
Figure S1 Weight modifications in control and
hSOD1
G93A mice. Weight changes in control (red) and
hSOD1
G93A (green) mice were weekly recorded from P56 to the
end of the life of the transgenic mice. Statistical analysis: data are
expressed as means 6 standard error of the mean (SEM), t-test, *
p,0.05, ** p,0.01, *** p,0.001.
(TIF)
Figure S2 FACS analysis of astrocytes in control and
hSOD1
G93A mice spinal cords at pre-symptomatic age.
The number of spinal astrocytes from hSOD1
G93A animals and
their control littermates was assessed by flow cytometry using the
pan-astrocyte marker Aldh1L1. (A–C) - Representative flow
cytometry analysis dot plot astrocyte profiles. A - Negative control
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astrocytes at P30. In both B - Controls and C hSOD1
G93A
surrounded areas, designed as ‘‘P3’’, correspond to the labeled
cells. The X-axis represents the intensity of fluorescence and the
Y-axis the size of the cells.
(TIF)
Figure S3 FACS analysis of GFAP
+ astrocytes in control
and hSOD1
G93A mice spinal cords. (A–C) - Representative
flow cytometry analysis dot plot astrocyte profiles at P30. A -
Negative control (without GFAP staining). B - Control and C -
hSOD1
G93A spinal astrocytes. (E–G) - Representative flow
cytometry analysis dot plot astrocyte profiles at P60. E - Negative
control (without GFAP staining). F - Control and G - hSOD1
G93A
spinal astrocytes. (I–K) - Representative flow cytometry analysis
dot plot astrocyte profiles at P120. I - Negative control (without
GFAP staining). J - Control and K - hSOD1
G93A spinal astrocytes.
In all profiles, surrounded areas, designed as ‘‘P3’’, correspond to
the labeled cells. (D, H, L) - Quantifications of GFAP
+- astrocytes
in control and hSOD1
G93A animals at D - pre-symptomatic (P30),
H - early-symptomatic (P60) and L - end-stages. The X-axis
represents the intensity of fluorescence and the Y-axis the size of
the cells. Statistics: t-test; *p,0.05.
(TIF)
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